How it works:
Ibrutinib blocks Bruton’s tyrosine kinase (BTK), a critical component of B-cell receptor signalling, leading to inhibition of tumour B-cell survival and proliferation. It is a cornerstone in the treatment of multiple haematologic cancers and is administered orally on a long-term basis.
Recommended for:
Patients with chronic lymphocytic leukaemia (CLL)
Patients with mantle cell lymphoma (MCL)
Patients with Waldenström’s macroglobulinemia (WM)
Individuals requiring targeted therapy after other treatments fail
Long-term management under haematologist supervision
Chronic lymphocytic leukaemia (CLL)
Mantle cell lymphoma
Waldenström’s macroglobulinemia
Marginal zone lymphoma (select cases)
Take orally once daily at the same time. Swallow the tablet whole with water, without crushing or chewing. Treatment is continuous and should be monitored regularly for efficacy and side effects by a haematologist.
Known hypersensitivity to ibrutinib or any excipients
Severe hepatic impairment
Pregnancy and breastfeeding
Untreated active infections
Use with strong CYP3A4 inhibitors without dose adjustment
Diarrhoea, nausea
Bleeding events (e.g., nosebleeds, GI bleeding)
Fatigue
High blood pressure
Respiratory tract infections
Rash and skin itching
Rare: atrial fibrillation, neutropenia
